Collaboration: Iktos and Italfarmaco

Italfarmaco SpA and Iktos have announced a collaboration to develop next-generation HDAC inhibitors for non-oncological diseases, leveraging Iktos’s AI-driven Makya and Spaya platforms for innovative molecule design and synthesis. This partnership aims to accelerate drug discovery and optimize resource utilization, with a focus on diseases affecting the central nervous system. Follow the link for the full press release.